Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma

Default sub title

minute read

Written by Targeted Oncology on November 16, 2022

During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.

Topics: Press Coverage

Comments